Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\VEGF.php on line 2
VEGF
LE WE PMID CA
VEGF2874VEGF

Aflibercept

Angiogenesis

Angiopoietin1

Apoptosis

Axitinib

AZD2171

Bevacizumab ttVEGF

bFGF

Blood vessels (Permeability)

CLC1 cardiotrophin like cytokine1

CNS (Neoplasia Glioblastoma)

Diabetes mellitus (Involvement kidney)

Embryology (BASKET)

Eye and orbita (Neovascularization)

Galactose

Hemopexin

Interleukin24 MDA7

JNK

Kidney (Glomerulus)

Kidney (Minimal change nephrotic syndrome)

Kidney (Pathology)

Kidney (Podocytes)

ORAI1 CRACM1

Ovary (Neoplasia)

Pegaptanib

Radiation therapy

Ranibizumab ttVEGF

Receptor (Urokinase)

Sorafenib

Src

Sunitinib

Tivozanib ttVEGF

Vadetanib

VEGF

2003  
1
Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease.
[12872442] Korean J Intern Med 18(2): 65-75 (2003)
2005  
2
Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors.
[15664382] Cardiovasc Res 65(3): 564-73 (2005)
2005  
3
The biology of vascular endothelial growth factors.
[15664381] Cardiovasc Res 65(3): 550-63 (2005)
2001  
4
Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.
[11166270] Cardiovasc Res 49(3): 568-81 (2001)
2004  
5
Vascular endothelial growth factor and angiogenesis.
[15602010] Pharmacol Rev 56(4): 549-80 (2004)
2010  
6
The VEGF family in cancer and antibody-based strategies for their inhibition.
[20190566] MAbs 2(2): 165-75 (2010)
2008  
7
Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention.
[19223981] Mediators Inflamm 2008(-): 129873 (2008)
2005  
8
Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events.
[16400523] Angiogenesis 8(4): 315-26 (2005)
2001  
9
Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro.
[11824379] Angiogenesis 4(1): 53-60 (2001)
2007  
10
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
[17615535] Cancer Control 14(3): 285-94 (2007)
2007  
11
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
[17671152] Clin Cancer Res 13(15 Pt 2): s4617-22 (2007)
2007  
12
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
[17374728] Mol Cancer Res 5(3): 203-20 (2007)
2004  
13
Vascular endothelial growth factor: basic science and clinical progress.
[15294883] Endocr Rev 25(4): 581-611 (2004)
1997  
14
The biology of vascular endothelial growth factor.
[9034784] Endocr Rev 18(1): 4-25 (1997)
1999  
15
Vascular endothelial growth factor (VEGF) and its receptors.
[9872925] FASEB J 13(1): 9-22 (1999)
2001  
16
The splice variants of vascular endothelial growth factor (VEGF) and their receptors.
[11181169] J Cell Sci 114(Pt 5): 853-65 (2001)
1995  
17
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
[7538264] Am J Pathol 146(5): 1029-39 (1995)
2001  
18
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.
[11350732] Am J Physiol Cell Physiol 280(6): C1375-86 (2001)
2001  
19
Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis.
[11350731] Am J Physiol Cell Physiol 280(6): C1367-74 (2001)
2001  
20
Role of vascular endothelial growth factor in regulation of physiological angiogenesis.
[11350730] Am J Physiol Cell Physiol 280(6): C1358-66 (2001)
2001  
21
Vascular endothelial growth factor: molecular underpinning from development of vasculature to development of disease.
[11350729] Am J Physiol Cell Physiol 280(6): C1357 (2001)
2006  
22
Homeostatic functions of vascular endothelial growth factor in adult microvasculature.
[16403945] Am J Physiol Heart Circ Physiol 290(2): H509-11 (2006)
2006  
23
Vascular endothelial growth factor in the lung.
[16403941] Am J Physiol Lung Cell Mol Physiol 290(2): L209-21 (2006)
2005  
24
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
[15471951] Blood 105(4): 1383-95 (2005)
2005  
25
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
[15693956] Genome Biol 6(2): 209 (2005)
2003  
26
Another possibly important function of VEGF related to polyneuropathy.
[14714950] Intern Med 42(12): 1161-2 (2003)
1996  
27
Vascular endothelial growth factor, a potent and selective angiogenic agent.
[8557658] J Biol Chem 271(2): 603-6 (1996)
2006  
28
Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis.
[16937487] World J Gastroenterol 12(31): 4937-42 (2006)
2006  
29
Biology of vascular endothelial growth factors.
[16631753] FEBS Lett 580(12): 2879-87 (2006)
2007  
30
Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine.
[17349880] J Am Coll Cardiol 49(10): 1015-26 (2007)
2007  
31
A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
[17951900] Indian J Ophthalmol 55(6): 437-9 (2007)
1997  
32
Role of vascular permeability factor/vascular endothelial growth factor in eye disease.
[9274417] Br J Ophthalmol 81(6): 501-12 (1997)
2010  
33
VEGF receptors and glomerular function.
[20847145] J Am Soc Nephrol 21(10): 1599-600 (2010)
2002  
34
VEGF is an essential molecule for glomerular structuring.
[12386279] Nephrol Dial Transplant 17 Suppl 9(-): 25-7 (2002)
2007  
35
Sympathetic control of VEGF angiogenic signaling: dual regulations by alpha 2-adrenoceptor activation?
[17901366] Circ Res 101(7): 642-4 (2007)
2007  
36
Silky, sticky chimeras-designer VEGFs display their wares.
[17525378] Circ Res 100(10): 1402-4 (2007)
2008  
37
Epigenetic regulation of vascular endothelial gene expression.
[18436802] Circ Res 102(8): 873-87 (2008)
2011  
38
Anti-VEGF therapy in breast and lung mouse models of cancers.
[21076538] J Biomed Biotechnol 2011(-): 947928 (2011)
2009  
39
2010  
40
Vascular endothelial growth factors and vascular permeability.
[20400620] Cardiovasc Res 87(2): 262-71 (2010)
2009  
41
Role and therapeutic potential of VEGF in the nervous system.
[19342615] Physiol Rev 89(2): 607-48 (2009)
2007  
42
Vascular endothelial growth factor: biology and therapeutic applications.
[17537667] Int J Biochem Cell Biol 39(7-8): 1349-57 (2007)
2010  
43
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
[20547589] Oncologist 15(7): 683-94 (2010)
2010  
44
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
[20139170] Oncologist 15(2): 130-41 (2010)
2007  
45
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
[17912242] Br J Cancer 97(7): 978-85 (2007)
2002  
46
Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage.
[12162725] J Anat 200(6): 575-80 (2002)
2002  
47
Regulation of microvascular permeability by vascular endothelial growth factors.
[12162726] J Anat 200(6): 581-97 (2002)
2009  
48
Aflibercept in epithelial ovarian carcinoma.
[19519199] Future Oncol 5(5): 591-600 (2009)
2007  
49
Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease.
[17545302] Am J Physiol Renal Physiol 292(6): F1665-72 (2007)
2010  
50
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.
[20966123] Clin J Am Soc Nephrol 5(11): 2115-21 (2010)
2005  
51
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
[16054437] Mol Ther 12(4): 707-15 (2005)
2004  
52
Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation.
[15194048] Mol Ther 9(6): 818-28 (2004)
2008  
53
Role of VEGF in organogenesis.
[19337405] Organogenesis 4(4): 247-56 (2008)
2011  
54
Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation.
[21441136] Circ Res 108(10): 1190-8 (2011)
2009  
55
The importance of cellular VEGF bioactivity in the development of glomerular disease.
[19590237] Nephron Exp Nephrol 113(1): e8-e15 (2009)
2007  
56
2009  
57
Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
[19671039] Expert Opin Investig Drugs 18(10): 1549-57 (2009)
2008  
58
Systems biology of vascular endothelial growth factors.
[18608994] Microcirculation 15(8): 715-38 (2008)
2011  
59
Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
[21318618] Curr Oncol Rep 13(2): 103-11 (2011)
2007  
60
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
[17462954] Trends Mol Med 13(6): 223-30 (2007)
2010  
61
Vascular endothelial growth factor pathway.
[20124951] Pharmacogenet Genomics 20(5): 346-9 (2010)
PMC   
62
Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.
[22703929] J Am Coll Cardiol 60(7):618-25 (2012)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\VEGF.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\VEGF.php on line 92